期刊文献+

Ang-2、Tie-2及VEGFR-2在大肠癌中的表达及与预后的关系 被引量:2

The relationship between prognosis and expression of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer
在线阅读 下载PDF
导出
摘要 目的检测Ang-2、Tie-2及VEGFR-2在大肠癌组织中的表达,分析其与大肠癌复发、转移的关系。方法采用免疫组化SP法检测54例大肠癌组织、18例大肠癌旁组织中Ang-2、Tie-2、VEGFR-2的表达,探讨其与大肠癌预后的关系。结果①Ang-2、Tie-2、VEGFR-2在大肠癌组织中的阳性表达率分别为77.78%、74.07%及59.26%,显著高于癌旁正常组织的阳性表达率的27.28%、16.67%及22.22%,差异均有统计学意义(P<0.05)。②Ang-2、Tie-2及VEGFR-2在根治术后5年内发生复发转移者的阳性表达率分别为87.50%、75.00%和75.00%,显著高于未复发转移组阳性表达率(分别为44.44%及22.22%、33.33%),差异均有统计学意义(P<0.05)。③Kaplan-Meier生存分析结果表明,Ang-2、Tie-2及VEGFR-2表达阴性者5年生存率均明显高于阳性表达者(P<0.05)。结论 Ang、Tie-2及VEGFR-2的表达与大肠癌复发转移及预后密切相关,可作为预测侵袭转移及评估预后的分子生物学标志物。 Objective To study the expression of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer,and to analyze the relationship between them with recurrence,metastasis and prognosis of colorectal cancer.Methods The expressions of Ang-2,Tie-2 and VEGFR-2 were studied by using immunohistochemical SP in 54 cases with colorectal cancer and in 18 cases of neighboring colorectal cancer tissue.Results The positive rate of Ang-2,Tie-2 and VEGFR-2 in colorectal cancer tissue were respectively 77.78%,74.07% and 59.26%,which were significantly higher than those in neighboring colorectal cancer tissue(positive rate were respectively 27.28%、 16.67% and 22.22%)(P0.05).The positive rate of Ang-2,Tie-2 and VEGFR-2 in patients who had recurrence metastasis after curative operation within 5 years were respectively 87.50%,75.00% and 75.00%,which were obviously higher than those in non-recurrence metastasis groups positive expression(positive rate were respectively 44.44%,22.22% and 33.33%)(P0.05).The results of Kaplan-Meier survival analysis showed that five-year overall survival rates of patients who had negative expression of Ang-2,Tie-2 and VEGFR-2 were obviously higher than those who had positive expression(P0.05).Conclusion The expression of Ang-2,Tie-2 and VEGFR-2 are closely correlated to the recurrence metastasis and prognosis of colorectal cancer,all of them could be the molecular markers for both predicting invasion metastasis and assessing prognosis.
出处 《宁夏医学杂志》 CAS 2012年第4期295-297,F0003,共4页 Ningxia Medical Journal
基金 宁夏自然科学基金资助项目(NZ0899)
关键词 大肠癌 血管生成素-2 血管生成素受体-2 血管内皮细胞生长因子受体-2 免疫组化 Colorectal Cancer Angiogenin-2 Tyrosine Kinase with Immunoglobulin-like and Epidermal Growth Factor Homology Domains Vascular Endothelial Growth Factor-2
  • 相关文献

参考文献5

二级参考文献65

  • 1陈立波,杨镇,王国斌,王春友.Expression of Angiopoietin-2 Gene and Its Receptor Tie2 in Hepatocellular Carcinoma[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2001,21(3):228-230. 被引量:2
  • 2Edge SB,Byrd DR,Compton CC,et al.AJCC Cancer Staging Manual.7th ed.New York:Springer,2010.
  • 3Greene FL,Page DL,Fleming ID,et al.AJCC Cancer Staging Manual.6th ed.New York:Springer,2002.
  • 4Greene FL,Page DL,Fleming ID,et al.AJCC 肿瘤分期手册.6版.沈阳:辽宁科技出版社,2005:225-228.
  • 5Greene FL,Stewart AK,Norton HJ.A new TNM staging strategy for node-positive (stage Ⅲ) colon cancer:an analysis of 50,042 patients.Ann surg,2002,236(4):416-421.
  • 6French AJ,Sargent DJ,Burgart LJ,et al.Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.Clin Cancer Res,2008,14(11):3408-3415.
  • 7Thibodeau SN,Bren G,Schaid D.Microsatellite instability in cancer of the proximal colon.Science,1993,260(5109):816-819.
  • 8Hailing KC,French AJ,McDonnell SK,et al.Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers.J Natl Cancer Inst,1999,91(1):1295-1303.
  • 9Gray RG,Barnwell J,Hills R,et al.QUASAR:A randomized study of adjuvant chemotherapy (CT) vs observation including 3238 colorectal cancer patients.Journal of Clinical Oncology,2004,22(14S):3501.
  • 10Andre T,Boni C,Navarro M,et al.Improved overall survival with oxaliplatin,fluorouracil,and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial.J Clin Oncol,2009,27(19):3109-3116.

共引文献89

同被引文献50

  • 1郝凤进,张勇.CD147与MMP-9蛋白在大肠癌中的表达[J].中国医科大学学报,2009,38(5):321-323. 被引量:4
  • 2宫媛,吴本俨.循证医学评价结肠癌辅助化疗药物及新进展[J].中国新药杂志,2007,16(10):757-761. 被引量:7
  • 3Zuckerman DS,Clark JW.Systemic therapy for metastatic colorectal cancer:current questions[J].Cancer,2008,12(9):1879-1891.
  • 4Sorokin P.New agents and future directions in biotherapy [J].Clin J Oncol Nurs,2002,6(1):19-24.
  • 5Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis[J].Eur J Cancer,2001,37(1):S9-S15.
  • 6Goldstein NS,Armin M.Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma:implications for a standardized scoring system[J].Cancer,2001,92:1331-1346.
  • 7Alberts SR.Effect of oxaliplatin,fluorouracil,and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer:a randomized trial[J].JAMA,2012,307(13):1383-1393.
  • 8Bentley TG,Broder MS,Das L,et al.Targeted therapies for metastatic colorectal cancer(mCRC):A systematic review of cost-effectiveness(CE)[J].J Clin Oncol,2012,30(4 suppl):583.
  • 9Siena S,Tabernero J,Cunningham D,et al.Randomized phase III study of panitumumab(pmab)with FOLFOX4 compared to FOLFOX4 alone as first-line treatment(tx)for metastatic colorectal cancer(mCRC):PRIME trial analysis by epidermal growth factor receptor(EGFR)tumor staining [J].J Clin Oncol,2010,28(Suppl 15s):3566.
  • 10Van Cutsem E,Peeters M,Siena S,et al.Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-re-fractory metastatic colorectal cancer [J].J Clin Oncol,2007,25(13):1658-1664.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部